CIBC Private Wealth Group’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

CIBC Private Wealth Group’s Portfolio BLPH Stock Details BLPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-833	Closed	-$14K	–	985
2018 Q3	$14K	Hold	833	–	–	﹤0.01%	959
2018 Q2	$30K	Hold	833	–	–	﹤0.01%	1310
2018 Q1	$26K	Hold	833	–	–	﹤0.01%	1327
2017 Q4	$32K	Hold	833	–	–	﹤0.01%	1302
2017 Q3	$18K	Buy	+833	New	+$15.5K	﹤0.01%	919

Other funds holding BLPH

NMVA

New Mountain Vantage Advisers New York $4.33B AUM 35.3% 1-Year Est. Return

PCM

Puissance Capital Management New York $17.3M AUM 149.36% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

VMI

VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

CIBC Private Wealth Group's BLPH Position: Q4 2018 in Review

CIBC Private Wealth Group sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q4 2018, closing a stake of 833 shares — an estimated $14K sold.

CIBC Private Wealth Group first reported a position in BLPH in Q3 2017 and held it in 5 quarters. The position peaked at $32K in Q4 2017. 25 funds tracked by Wall St. Rank hold BLPH as of Q4 2018.

CIBC Private Wealth Group reported no remaining Bellerophon Therapeutics, Inc. position as of Q4 2018 after selling out during the quarter.
CIBC Private Wealth Group sold 833 Bellerophon Therapeutics, Inc. shares in Q4 2018, an estimated $14K.
CIBC Private Wealth Group first reported a position in Bellerophon Therapeutics, Inc. in Q3 2017 and held it in 5 quarters.
CIBC Private Wealth Group's Bellerophon Therapeutics, Inc. position peaked at $32K in Q4 2017.
25 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q4 2018.

Based on CIBC Private Wealth Group's 13F filing for Q4 2018, filed 5 Feb 2019.